Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032

PLX4032/vemurafenib is a first-in-class small-molecule BRAF(V600E) inhibitor with clinical activity in patients with BRAF mutant melanoma. Nevertheless, drug resistance develops in treated patients, and strategies to overcome primary and acquired resistance are required. To explore the molecular mec...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Vergani, Elisabetta, Vallacchi, Viviana, Frigerio, Simona, Deho, Paola, Mondellini, Piera, Perego, Paola, Cassinelli, Giuliana, Lanzi, Cinzia, Testi, Maria Adele, Rivoltini, Licia, Bongarzone, Italia, Rodolfo, Monica
Format: Artigo
Langue:Inglês
Publié: Neoplasia Press Inc. 2011
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3257188/
https://ncbi.nlm.nih.gov/pubmed/22241959
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires